Baraclude(entecavir)
Baraclude (entecavir) is a small molecule pharmaceutical. Entecavir was first approved as Baraclude on 2005-03-29. It is used to treat chronic hepatitis b and hepatitis b in the USA. It has been approved in Europe to treat chronic hepatitis b and hepatitis b.
Download report
Favorite
BMS
Commercial
Trade Name
FDA
EMA
Baraclude (generic drugs available since 2015-08-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
| hepatitis b | — | D006509 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
220 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | 18 | 33 | 16 | 48 | 20 | 127 |
| Hepatitis b | D006509 | 4 | 9 | 9 | 11 | 15 | 47 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 7 | 5 | 12 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 3 | 3 | 4 | 10 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 2 | 1 | 2 | 2 | 6 |
| Hepatitis b virus | D006515 | 1 | 2 | — | 2 | 1 | 6 | ||
| Chronic hepatitis | D006521 | K73.9 | 1 | — | 1 | 1 | 1 | 4 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 1 | 2 | — | 3 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 1 | 1 | 3 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | 1 | 1 | 3 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic disease | D002908 | — | — | 1 | — | 1 | 2 | ||
| B-cell lymphoma | D016393 | — | — | 1 | — | — | 1 | ||
| Juvenile arthritis | D001171 | EFO_0002609 | M08 | — | — | 1 | — | — | 1 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 1 | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 | |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver failure | D017093 | HP_0001399 | K72.9 | — | 1 | — | — | 1 | 2 |
| Chronic hepatitis d | D019701 | — | 1 | — | — | — | 1 | ||
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Hepatitis d | D003699 | EFO_0007304 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ENTECAVIR |
| INN | entecavir |
| Description | Entecavir (ETV), sold under the brand name Baraclude, is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection. In those with both HIV/AIDS and HBV antiretroviral medication should also be used. Entecavir is taken by mouth as a tablet or solution.
|
| Classification | Small molecule |
| Drug class | antivirals: carbocyclic nucleosides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO |
Identifiers
| PDB | — |
| CAS-ID | 142217-69-4 |
| RxCUI | 1546027 |
| ChEMBL ID | CHEMBL713 |
| ChEBI ID | 473990 |
| PubChem CID | 153941 |
| DrugBank | DB00442 |
| UNII ID | NNU2O4609D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Baraclude - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,818 documents
View more details
Safety
Black-box Warning
Black-box warning for: Baraclude, Entecavir
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,566 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more